Delayed-release DMF exerts anti-inflammatory and neuroprotective properties for the treatment of relapsing multiple sclerosis, a disease that often develops in women between the ages of 20 and 40.
The post-hoc analyses found Ocrevus to significantly decrease disease activity and disability progression in patients with RMS and PPMS, as assessed by No Evidence of Progression or Active Disease (NEPAD), a new composite endpoint in MS.
This new software allows patients currently using the electronic BETACONNECT autoinjector to administer Betaseron (interferon beta-1b) to connect their autoinjector to the new myBETAapp through their mobile device or computer.
The Radiance trial included 1,313 relapsing multiple sclerosis (RMS) patients who were administered either 0.5mg or 1mg of oral ozanimod, or weekly intramuscular interferon beta-1a (Avonex) over a 2 year treatment period.
Cheong noted that only 1 patient was non-adherent. There was an increase in patient knowledge scores, from a mean baseline score of 20.14 to 31.67 (P<0.05) by the end of the third appointment.
Among patients with early relapsing multiple sclerosis patients, Ocrevus suppressed >90% of active MRI lesions over 2 years vs. interferon beta-1a.
The majority of patients who relapsed between courses were free of confirmed disability worsening (CDW) in Year 2 and 60% remained free of CDW by Year 6.
Study patients treated with Aubagio 14mg and 7mg had a significantly reduced risk of developing clinically definite MS vs. placebo (P<0.05).
Over 6 months, the researchers said, none of the patients suffered serious side effects from the treatment. In addition, 3 showed symptom improvements within 2 to 8 weeks of their first T-cell infusion.
The researchers found that maternal illness during pregnancy correlated with 2.3-fold increased odds of having mulitple sclerosis.
Patients with autoimmune diseases appear to have an increased risk of developing dementia, according to a study published online March 1 in the Journal of Epidemiology & Community Health.
The investigational multiple sclerosis (MS) therapy cladribine tablets (Merck) has shown efficacy in reducing annualized rate of brain atrophy when compared to placebo in patients with relapsing remitting multiple sclerosis (RRMS).
The Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Gilenya (fingolimod; Novartis) capsules regarding its Risk Evaluation and Mitigation Strategy (REMS) assessment.
The multiple sclerosis (MS) drug alemtuzumab, usually reserved for patients in the late stages of the disease, seems to offer long-term remission in newly diagnosed patients, according to a study published online October 12 in Neurology.
Regular physical activity won't lower the risk of multiple sclerosis (MS) in women, according to research published online in Neurology.
An experimental drug, laquinimod, appears to prevent or slow the progression of multiple sclerosis (MS) in mice, according to a study published online in Neurology: Neuroimmunology & Neuroinflammation.
Genentech announced new study analyses from ORCHESTRA, the Phase 3 clinical development program for Ocrevus (ocrelizumab) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
For patients with multiple sclerosis (MS), magnetic resonance imaging (MRI) and clinical assessments do not appear to offer long-term prognostic value, according to a study published online July 27 in the Annals of Neurology.
The Food and Drug Administration (FDA) is warning against misleading claims about whole body cryotherapy to treat various diseases or conditions.